Why a trial was needed
By 1953 Jonas Salk’s inactivated polio vaccine had been tried on small groups, including children already recovered from polio and some volunteers. Those tests suggested it was safe and produced antibodies, but antibodies in the blood are not the same as proof of protection from disease. Polio also came in unpredictable waves, so a drop in cases after vaccination could be coincidence. To know whether the vaccine worked, researchers needed a very large test with a comparison group.
The National Foundation for Infantile Paralysis, the charity behind the March of Dimes, organized and paid for the trial. It was among the largest public health experiments of its era, and it used donations from the public. The overall story of the vaccine, including Albert Sabin’s oral version, is told elsewhere on this site; this article is about the test itself.
Two designs at once
The trial in spring 1954 used two different designs in different parts of the country. The reason was partly scientific and partly political, because experts disagreed about whether a placebo was necessary.
- Placebo-controlled areas. Children in the first through third grades whose parents consented were randomly assigned to receive either vaccine or an injection that looked identical but contained no vaccine, only an inactive solution. The code was kept secret, so that neither the children, their families, the doctors giving the shots nor those diagnosing illness knew who got what. This is called a double-blind design.
- Observed-control areas. Second graders were offered the vaccine, while first and third graders were not, and became the comparison group. This was simpler and avoided giving anyone a dummy shot, but the groups might differ in ways that distort the result, such as differences in how reliably cases were reported.
Roughly 1.8 million children took part in some way. A few hundred thousand received vaccine, around 200,000 received placebo, and over a million served as controls or were observed. Children in the study became known as the “Polio Pioneers,” and received a button and a certificate. Volunteer physicians, nurses and teachers did much of the work, and doses were given in a series of three injections with a hypodermic syringe.
Keeping the vaccine safe
Safety testing was a major part of the work. Vaccine lots were produced by two pharmaceutical companies and checked before use, including tests designed to detect any live virus remaining after the formaldehyde treatment. In the weeks and months of the trial, the foundation tracked reactions and any cases of illness among participants.
The testing also depended on laboratory work. Poliovirus grown in cell cultures was used to check lots, and laboratories tried to confirm whether children who became sick actually had polio, since many illnesses in summer resemble it. Diagnoses were examined by committees that did not know whether the child had been vaccinated.
The evaluation
The evaluation was led by Thomas Francis Jr., a respected epidemiologist at the University of Michigan, who had been Salk’s mentor. He was chosen partly so the analysis would be independent of the vaccine’s developer and of the foundation. His team worked through the data over the winter of 1954 to 1955, comparing illness rates in the vaccinated and control groups while allowing for year-to-year variation in polio.
On April 12, 1955, in Ann Arbor, Francis announced the findings to a large audience, and the news was carried on radio broadcasting and television broadcasting across the country. The report said the vaccine was safe and effective. Effectiveness was reported as varying by poliovirus type, and it was generally described as strongest against types 2 and 3 and somewhat lower, though still substantial, against type 1. Within hours the U.S. government licensed the vaccine, and mass vaccination began.
What the trial showed and did not show
The trial gave the strongest evidence yet that an inactivated vaccine could protect against paralytic polio. It also set an example for how to test vaccines and other medicines: randomization, blinding and independent analysis were widely taught afterward as models.
It had limits, though. The two designs made comparison harder, and some critics questioned parts of the analysis at the time. The trial was not large enough to detect extremely rare harms. That issue became sharply apparent within days of licensing, when cases of polio were traced to vaccine from one manufacturer, Cutter Laboratories, which had failed to fully inactivate the virus. After that, vaccine production and testing rules were tightened, and the government expanded its oversight of vaccine makers.
Why it still matters
The 1954 trial turned a hopeful laboratory result into public confidence and set practical standards. It is also a reminder that testing is not a one-time event: effectiveness, manufacturing quality and long-term monitoring all matter. For readers curious about modern equivalents, the basic ideas of placebo control and blinding are still central to how vaccines are evaluated, though today’s trials follow stricter ethical rules and formal oversight that did not exist in the 1950s. This is history, not medical advice.